# Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

> **NCT07493512** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Amgen** · enrollment: 40 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Xaluritamig

## Key facts

- **NCT ID:** NCT07493512
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-26
- **Primary completion:** 2027-05-27
- **Final completion:** 2029-11-24
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07493512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07493512, "Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07493512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*